Lucigenin | 2315-97-1

• 物质功能分类: 生物化工 - 中草药成分
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: Lucigenin
• 英文别名: 10-methyl-9-(10-methylacridin-10-ium-9-yl)acridin-10-ium;dinitrate
• CAS: 2315-97-1
• 化学式: C28H22N4O6
• mdl: MFCD00011925
• 分子量: 510.5
• InChiKey: KNJDBYZZKAZQNG-UHFFFAOYSA-N

物化性质

• 熔点：
  250°C
• 溶解度：
  在醋酸中的溶解度为10mg/mL
• 最大波长(λmax)：
  455nm

计算性质

• 辛醇/水分配系数(LogP)：
  -2.63
• 重原子数：
  38
• 可旋转键数：
  1
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.071
• 拓扑面积：
  134
• 氢给体数：
  0
• 氢受体数：
  6

安全信息

• 危险等级：
  5.1
• 安全说明：
  S24/25
• WGK Germany：
  3
• 海关编码：
  29339900

制备方法与用途

生物活性

Lucigenin (NSC-151912, L-6868) 是一种荧光探针，当在细胞内源性产生的超氧阴离子自由基（superoxide anion radicals）和氯化物（chloride）存在的情况下，会发出蓝绿色的荧光。

靶点

Target	Value
超氧阴离子自由基	()
氯化物	()

反应信息

• 作为产物：
  描述：

  吖啶酮 生成 Lucigenin
  参考文献：
  名称：

  SHEN, JIANMIN;SUN, TIEMIN;CHEN, RONGLIANG;XU, XIAOQING, XUASYUEH SHITSZI, 10,(1988) N 3, S. 178-179

  摘要：

  DOI：

文献信息

• [EN] METHOD<br/>[FR] MÉTHODE
  申请人：UNIV OSLO HF

  公开号：WO2019243757A1

  公开（公告）日：2019-12-26

  The invention provides mitochondria-targeted chemiluminescent agents and their use in methods of photodynamic therapy (PDT). In particular, the invention provides compounds of general formula (I), and their pharmaceutically acceptable salts: (I) in which A represents a chemiluminescent moiety; each L, which may be the same or different, is either a direct bond or a linker; each B, which may be the same or different, represents a mitotropic moiety; n is an integer from 1 to 3, preferably 1; and x is an integer from 1 to 3, preferably 1. Such compounds find particular use in the treatment of deeply- sited tumours, e.g. glioblastoma multiforme (GBM), when used in combination with a photosensitizer or photosensitizer precursor.

  该发明提供了以线粒体为靶向的化学发光剂及其在光动力疗法（PDT）方法中的应用。具体而言，该发明提供了一般式（I）的化合物及其药学上可接受的盐：（I）其中A代表化学发光基团；每个L，可以相同也可以不同，要么是直接键要么是连接物；每个B，可以相同也可以不同，代表线粒体靶向基团；n是从1到3的整数，优选为1；x是从1到3的整数，优选为1。这类化合物在治疗深部肿瘤，例如胶质母细胞瘤（GBM）时，与光敏剂或光敏剂前体结合使用时具有特殊用途。
• [EN] INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION<br/>[FR] INHIBITEURS DE LA RÉPLICATION DU VIRUS DE L'IMMUNODÉFICIENCE HUMAINE
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2009062289A1

  公开（公告）日：2009-05-22

  Compounds of formula I : wherein c, R2, R3, R4, R5, R6, R7 and R8 are defined herein, are useful as inhibitors of HIV replication.

  公式I的化合物：其中c、R2、R3、R4、R5、R6、R7和R8按本说明定义，可用作HIV复制的抑制剂。
• [EN] NOVEL BIPHENYL SARTANS<br/>[FR] NOUVEAUX BIPHÉNYLSARTANS
  申请人：UNIV MELBOURNE

  公开号：WO2011134019A1

  公开（公告）日：2011-11-03

  The present invention relates to compounds and compositions useful in modulating the renin-angiotensin system (RAS) in cells, and in particular to compounds which, inter alia, act as angiotensin II antagonists by binding to angiotensin II receptors. The invention also relates to the use of these compounds and compositions in the treatment of conditions responsive to angiotensin II antagonists such as hypertension, edema, renal failure, benign prostatic hypertrophy glaucoma, atherosclerosis, diabetes, Alzheimer's disease and congestive heart failure.

  本发明涉及在细胞中调节肾素-血管紧张素系统（RAS）的化合物和组合物，特别是涉及一些作为血管紧张素II拮抗剂的化合物，通过结合血管紧张素II受体发挥作用。该发明还涉及在治疗对血管紧张素II拮抗剂敏感的疾病中使用这些化合物和组合物，如高血压、水肿、肾功能衰竭、良性前列腺增生、青光眼、动脉粥样硬化、糖尿病、阿尔茨海默病和充血性心力衰竭。
• A method of using synthetic L-SE-Methylselenocysteine as a nutriceutical and a method of its synthesis
  申请人：PharmaSe, Incorporated

  公开号：EP1205471A1

  公开（公告）日：2002-05-15

  A synthesis of and use of L-Se-methylselenocysteine as a nutriceutical is described, based upon the knowledge that L-Se-methylselenocysteine is less toxic than L-selenomethionine towards normal cells. The synthesis proceeds by mixing N-(tert-butoxycarbonyl)-L-serine with a dialkyl diazodicarboxylate and at least one of a trialkylphosphine, triarylphosphine and phosphite to form a first mixture that includes N-(tert-butoxycarbonyl)-L-serine β-lactone. Methyl selenol or its salt is mixed with the N-(tert-butoxycarbonyl)-L-serine β-lactone to form a second mixture that includes N-(tert-butoxycarbonyl)-Se-methylselenocysteine. The text butoxycarbonyl group is removed from the N-(tert-butoxycarbonyl)-Se-methylselenocysteine to form L-Se-methylselenocysteine. This synthesis significantly improves the manufacturability, manufacturing efficiency and utility of this naturally occurring rare form of organic-selenium. L-Se-methylselenocysteine formed, for example, in this manner may be used as a nutriceutical for supplementation into the diets of humans or animals for various beneficial purposes, such as, for example, to prevent or reduce the risk of developing cancer.

  描述了一种合成和使用L-Se-甲硒氨酸作为一种营养保健品，基于L-Se-甲硒氨酸对正常细胞比L-硒蛋氨酸毒性较小的知识。合成过程包括将N-(叔丁氧羰基)-L-丝氨酸与二烷基重氮二羧酸酯和三烷基膦、三芳基膦和磷酸酯中的至少一种混合，形成包含N-(叔丁氧羰基)-L-丝氨酸β-内酯的第一混合物。甲硒醇或其盐与N-(叔丁氧羰基)-L-丝氨酸β-内酯混合，形成包含N-(叔丁氧羰基)-Se-甲硒氨酸的第二混合物。将N-(叔丁氧羰基)-Se-甲硒氨酸中的叔丁氧羰基团去除，形成L-Se-甲硒氨酸。这种合成显著改善了这种天然存在的稀有有机硒形式的可制造性、制造效率和实用性。例如，以这种方式形成的L-Se-甲硒氨酸可用作一种营养保健品，添加到人类或动物的饮食中，以达到各种有益目的，例如预防或减少患癌症的风险。
• Reagents and methods for direct labeling of nucleotides
  申请人：Naleway John J.

  公开号：US20130150254A1

  公开（公告）日：2013-06-13

  The present invention provides systems and methods for production of activatable diazo-derivatives for use in labeling nucleotides. Labeling nucleotides is accomplished by contacting a stable hydrazide derivative of a detectable moiety with an activating polymer reagent which is used to directly label the nucleotide sample. Labeling occurs on the phosphate backbone of the nucleotide which does not perturb hybridization of the labeled nucleotide with its anti-sense strand. Since the method involves direct labeling, all types of nucleotides can be labeled without prior amplification or alteration.

  本发明提供了用于生产可激活重氮衍生物以用于标记核苷酸的系统和方法。通过将可检测基团的稳定的肼酰肼衍生物与用于直接标记核苷酸样品的活化聚合物试剂接触来完成核苷酸的标记。标记发生在核苷酸的磷酸骨架上，不会干扰标记核苷酸与其反义链的杂交。由于该方法涉及直接标记，所有类型的核苷酸都可以在不经过扩增或改变的情况下进行标记。

表征谱图